Mouse urogenital development: a practical approach

Staack, Andrea; Donjacour, Annemarie A.; Brody, Joel R.; Cunha, Gerald R.; Carroll, Peter R.

doi:10.1046/j.1432-0436.2003.7107004.x

Cited by 134 publications

(123 citation statements)

References 21 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…To address this goal a xenografting technique developed by the Vanderbilt MPSA site 18 was employed to specifically identify androgenregulated genes in benign human prostate tissues. Androgen regulation was chosen because of the key role that steroid hormones play in prostatic development and disease.…”

Section: Identification Of Androgen Regulated Proteins Secreted By Bementioning

confidence: 99%

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

et al. 2008

View full text Add to dashboard Cite

Purpose-Clinical benign prostatic hyperplasia (BPH) is primarily diagnosed based on a diverse array of progressive lower urinary tract symptoms (LUTS) and is likely distinct from histological BPH, which is detected by the presence of non-malignant proliferation of prostate cells but may or may not be associated with symptoms. Pharmacological management of LUTS has emerged as an effective initial treatment for clinical BPH due to the introduction of new drug therapies shown to be effective in recent large clinical trials. Despite advances in symptom management and research into BPH pathology, diagnostic strategies for prediction of BPH progression and response to drug modalities are lacking and questions remain as to the molecular differences underlying clinical (symptomatic) versus histological (non-symptomatic) BPH. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Results-To date the MPSA has identified a number of promising biomarkers and other molecular and cellular changes associated with BPH. NIH Public AccessConclusions-These findings and ongoing consortium discovery efforts have the potential to provide a greater understanding of the defects underlying disease pathology and may lead to the development of early and more effective pharmacological treatment strategies for BPH.

show abstract

Section: Identification Of Androgen Regulated Proteins Secreted By Bementioning

confidence: 99%

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The superior region of the developing urogenital sinus gives rise to the definitive bladder, while the intermediate and lower regions develop into the urethra in males and urethra and vagina in females. Bladder organogenesis is highly dependent upon the reciprocal interactions of embryonic endoderm and lateral plate mesoderm (Baskin et al, 1996;Staack et al, 2003). Embryonic endoderm gives rise to the bladder urothelium while the connective tissues and smooth muscle of the developing bladder are derived from the peri-cloacal mesenchyme (Haraguchi et al, 2007;Brenner-Anantharam et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Transcriptional profiling of the megabladder mouse: A unique model of bladder dysmorphogenesis

Singh¹,

Robinson²,

Ismail³

et al. 2007

Developmental Dynamics

View full text Add to dashboard Cite

Recent studies in our lab identified a mutant mouse model of obstructive nephropathy designated mgb for megabladder. Homozygotic mgb mice (mgb؊/؊) develop lower urinary tract obstruction in utero due to a lack of bladder smooth muscle differentiation. This defect is the result of a random transgene insertion/translocation into chromosomes 11 and 16. Transcriptional profiling identified a significantly over-expressed cluster of gene products located on the translocated fragment of chromosome 16 including urotensin II-related peptide (Urp), which was shown to be preferentially over-expressed in developing mgb؊/؊ bladders. Pathway analysis of mgb microarray data indicated dysregulation of at least 60 gene products associated with smooth muscle development. In conclusion, the results of this study indicate that the molecular pathways controlling normal smooth muscle development are severely altered in mgb؊/؊ bladders, and provide the first evidence that Urp may play a critical role in bladder smooth muscle development. Developmental Dynamics 237:170 -186, 2008.

show abstract

“…For bladder studies, tissue recombination involves the isolation of embryonic bladder mesenchyme (EBLM) from animals and subsequent recombination with human or murine urothelial carcinoma cells (81), transgenic urothelium, or benign but genetically manipulated urothelial cells. Following recombination, tissue grafts are inserted under the kidney capsule of either immune-compromised or syngeneic hosts and harvested at specific times for analysis (81). One of the major strengths of tissue recombination is the recapitulation of normal multilayered bladder transitional epithelium indicating relatively restricted lineage commitment and subsequent differentiation.…”

Section: Tissue Recombinationmentioning

confidence: 99%

Current Preclinical Models for the Advancement of Translational Bladder Cancer Research

DeGraff

Robinson

Shah

et al. 2013

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care.

show abstract

Mouse urogenital development: a practical approach

Cited by 134 publications

References 21 publications

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

Transcriptional profiling of the megabladder mouse: A unique model of bladder dysmorphogenesis

Current Preclinical Models for the Advancement of Translational Bladder Cancer Research

Contact Info

Product

Resources

About